Geode Capital Management LLC Acquires 14,319 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA)

Geode Capital Management LLC boosted its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 5.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 271,026 shares of the company’s stock after buying an additional 14,319 shares during the quarter. Geode Capital Management LLC owned approximately 0.56% of Ikena Oncology worth $469,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC bought a new position in shares of Ikena Oncology in the 2nd quarter worth $30,000. AQR Capital Management LLC purchased a new stake in shares of Ikena Oncology during the second quarter valued at about $36,000. FMR LLC boosted its holdings in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after buying an additional 18,607 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ikena Oncology in the 2nd quarter worth approximately $75,000. Finally, BBR Partners LLC raised its stake in shares of Ikena Oncology by 550.0% during the 3rd quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock worth $225,000 after acquiring an additional 110,000 shares in the last quarter. Institutional investors own 75.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IKNA. Wedbush restated a “neutral” rating and issued a $2.00 target price on shares of Ikena Oncology in a research note on Monday, December 23rd. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Ikena Oncology in a research report on Monday, November 11th.

Ikena Oncology Stock Down 2.5 %

IKNA opened at $1.56 on Monday. The company has a market cap of $75.28 million, a P/E ratio of -1.27 and a beta of 0.49. The firm’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.68. Ikena Oncology, Inc. has a 52-week low of $1.22 and a 52-week high of $2.03.

Ikena Oncology (NASDAQ:IKNA) last released its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.08. On average, research analysts anticipate that Ikena Oncology, Inc. will post -0.91 EPS for the current fiscal year.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.